Assessing the Efficacy and Safety of Photobiomodulation for the Treatment of Pruritus
ConditionPruritus
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorMassachusetts General Hospital
About this trial
This study is designed to evaluate the safety and effectiveness of a low-level near-infrared LED light device for relieving itch. The device is non-invasive, does not break the skin, and does not produce heat. Near-infrared light has been used in other medical settings and is known to interact with skin and nerve pathways. In this study, researchers are examining whether this light can be safely applied to the skin and whether it may help reduce itch by affecting signals involved in itch sensation.
Eligibility criteria
Qualifiers
Participant is an adult at least 18 years-of-age.
Acute itch lasting less than 6 weeks.
Chronic itch lasting more than 6 weeks.
Participant is able and willing to comply with all the study visit, treatment, and evaluation schedules and requirements.
Disqualifiers
Participant has any active internal or cutaneous malignancy located within the proposed treatment area.
Participant cannot provide informed consent or adhere to study schedule.
Participant is actively tanning during the study course.
Participant has melasma or another condition exacerbated by heat.
Trial design
Treatments tested in this trial
- Light-emitting diode (LED) Photobiomodulation (PBM) device
- Placebo
Treatment groups
20 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov